Nav: Home

What's the next step for exon skipping therapies to treat duchenne muscular dystrophy?

October 16, 2017

New Rochelle, NY, October 16, 2017--A team of leading European clinicians and scientists presents a unique perspective on how to move forward in the development of exon skipping therapies to treat the severe muscle-wasting disease Duchenne Muscular Dystrophy (DMD). Following recent approval by the U.S. regulatory authorities of the first such drug for DMD, the team of authors representing key European regulatory agencies, academic medical centers, industry, and patient groups discusses the main challenges and opportunities for the development and regulatory approval of these therapeutic agents going forward, in an article published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers The article is available free on the Nucleic Acid Therapeutics website.

The article entitled "Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues," was coauthored by Annemieke Aartsma-Rus, PhD, Co-Editor-in-Chief of Nucleic Acid Therapeutics, Pavel Balabanov, MD, PhD, and colleagues from Leiden University Medical Center (The Netherlands), Newcastle University (Newcastle upon Tyne, U.K.), Medicines and Healthcare Product Regulatory Agency (London, U.K.), European Medicines Agency, Bundesinstitut für Arzneimittle und Medizinprodukte (Bonn, Germany), Medicines Evaluation Board (Utrecht, The Netherlands), Catholic University and Centro Clinico Nemo (Rome, Italy), UCL Great Ormond Street Institute of Child Health (London, U.K.), Universidade de Lisboa, Faculdade de Farmácia (Portugal), and United Parent Project Muscular Dystrophy (Amsterdam, The Netherlands).

The authors review the mechanism of action, effectiveness, and limitations of the first-in-class antisense oligonucleotide (AON) drug eteplirsen, which targets exon 51 in patients with DMD. Only 13-14% of patients with DMD have a mutation in exon 51 and would benefit from this treatment, with other small patient clusters requiring distinct AON drugs that each target a different exon. Based on the most recent scientific and medical evidence in the field and the views expressed by European regulators, the authors offer their perspective on the most efficient strategy for developing future exon skipping drugs for DMD, which would deliver effective treatments to patients as quickly as possible. The discussion includes the use of biomarkers in AON drug development, approaches for developing AONS for very small groups of patients, regulatory tools and incentives in the EU, and the potential for obtaining "class" or "platform" approval for AON drugs.

"This paper exemplifies the journal's commitment to advancing the field through consensus, or where necessary, healthy debate among all stakeholders. The piece can also be seen as a call for more candid dialogue with regulatory agencies," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
-end-
About the Journal

Nucleic Acid Therapeutics is an authoritative peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society . Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics (http://www.liebertpub.com/nat) website.

About the Society

The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Assay and Drug Development Technologies, Applied In Vitro Toxicology, and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website .

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle
NY 10801-5215
Phone: 914-740-2100
(800) M-LIEBERT
Fax: 914-740-2101http://www.liebertpub.com

Mary Ann Liebert, Inc./Genetic Engineering News

Related Nucleic Acid Therapeutics Articles:

New method accelerates development of protein therapeutics
Northwestern Engineering researchers have developed a quick, cell-free system to create biosynthetic pathways to build and study sugar structures.
New insights into the structure and function of Cdc34, a target for cancer therapeutics
Medical University of South Carolina researchers report in Nature Communications they have obtained 3D structural snapshots of Cdc34 in action.
Elicio Therapeutics' Darrell Irvine co-authors research published in Science
Elicio Therapeutics, a next generation immuno-oncology company, today announced that studies of its Amphiphile platform in combination with CAR-T therapy (AMP-CAR-T) have shown that activation of CAR-T cells in the lymphatic system gives massive CAR-T cell expansion, and significant functional improvements including enhanced CAR-T cell infiltration of solid tumors, increased anti-tumor cytolytic potential, and improved cytokine response.
'Green Revolution' in RNAi tools and therapeutics
A team from Nanjing University in China reported that the small silencing RNA sequences against HBsAg generated in edible lettuce (Lactuca sativa L.) can specifically bind and inhibit gene expression in p21-HBsAg knock-in transgenic mice and improve liver injury at a relatively low level when compared to synthetic siRNAs.
Best practices of nucleic acid amplification tests for the diagnosis of clostridioides (clostridium)
A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests.
Texas A&M research team develops bioinks to print therapeutics in 3D
A team of researchers at Texas A&M University has developed an innovative way to print therapeutics in 3D for regenerative medicine.
New guidelines push for better controlled experiments with synthetic nucleic acids
Researchers have proposed new guidelines to overcome current problems facing scientists developing synthetic nucleic acids -- such as antisense oligonucleotides and double-stranded RNAs -- as drugs and research tools.
Yumanity Therapeutics announces publication of paper in Cell Reports
Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, today announced the publication of study results describing a potential new target for therapeutic intervention in Parkinson's disease and other related disorders.
stem cells can differentiate into neurons and may be useful post-stroke therapeutics
Researchers have performed a careful comparison between locally generated, ischemia-induced, multipotent stem cells (iSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) in an effort to determine which cell type has greater central nervous system (CNS) repair capacity.
Scientists discover intricacies of serotonin receptor crucial for better therapeutics
For the first time, scientists have figured out why drugs that aim to treat Parkinson's disease, migraines, pituitary tumors, and obesity activate the serotonin receptor 5-HT2B to cause life-threatening heart problems.
More Nucleic Acid Therapeutics News and Nucleic Acid Therapeutics Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab